D. E. Shaw & Co. Inc. lowered its stake in shares of Nuvalent, Inc. (NASDAQ:NUVL – Free Report) by 10.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 399,199 shares of the company’s stock after selling 46,183 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Nuvalent were worth $30,283,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Rhenman & Partners Asset Management AB increased its holdings in shares of Nuvalent by 31.3% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 112,929 shares of the company’s stock valued at $8,310,000 after purchasing an additional 26,918 shares during the period. Renaissance Capital LLC acquired a new position in Nuvalent in the 1st quarter valued at $1,301,000. Parkman Healthcare Partners LLC purchased a new position in Nuvalent during the 4th quarter worth $4,406,000. Commodore Capital LP lifted its stake in shares of Nuvalent by 60.6% in the 4th quarter. Commodore Capital LP now owns 1,331,037 shares of the company’s stock worth $97,951,000 after acquiring an additional 502,259 shares during the period. Finally, Edgestream Partners L.P. purchased a new stake in shares of Nuvalent in the second quarter valued at about $1,191,000. 97.26% of the stock is owned by hedge funds and other institutional investors.
Nuvalent Trading Down 1.9 %
Shares of NASDAQ NUVL opened at $99.10 on Friday. The company’s 50-day moving average price is $84.32 and its 200 day moving average price is $77.04. Nuvalent, Inc. has a 52 week low of $41.16 and a 52 week high of $113.51. The stock has a market cap of $6.40 billion, a price-to-earnings ratio of -41.12 and a beta of 1.28.
Analyst Ratings Changes
A number of equities research analysts recently commented on the stock. Lifesci Capital upgraded shares of Nuvalent to a “strong-buy” rating in a research report on Monday, July 29th. The Goldman Sachs Group raised Nuvalent to a “strong sell” rating in a report on Monday, September 16th. JPMorgan Chase & Co. upped their price objective on Nuvalent from $90.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Wedbush raised their target price on Nuvalent from $99.00 to $115.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Finally, Stifel Nicolaus increased their price target on shares of Nuvalent from $115.00 to $135.00 and gave the company a “buy” rating in a report on Monday, September 16th. One analyst has rated the stock with a sell rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $111.00.
View Our Latest Analysis on Nuvalent
Insiders Place Their Bets
In other news, Director Matthew Shair sold 2,000 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $102.75, for a total value of $205,500.00. Following the sale, the director now directly owns 226,522 shares in the company, valued at $23,275,135.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Alexandra Balcom sold 10,000 shares of Nuvalent stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $79.51, for a total transaction of $795,100.00. Following the completion of the sale, the chief financial officer now directly owns 33,300 shares in the company, valued at $2,647,683. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Matthew Shair sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $102.75, for a total transaction of $205,500.00. Following the completion of the transaction, the director now directly owns 226,522 shares of the company’s stock, valued at approximately $23,275,135.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 107,629 shares of company stock valued at $9,352,958. Corporate insiders own 12.52% of the company’s stock.
Nuvalent Profile
Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.
Featured Articles
- Five stocks we like better than Nuvalent
- How to Calculate Stock Profit
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Business Services Stocks Investing
- MarketBeat Week in Review – 9/23 – 9/27
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Want to see what other hedge funds are holding NUVL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvalent, Inc. (NASDAQ:NUVL – Free Report).
Receive News & Ratings for Nuvalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvalent and related companies with MarketBeat.com's FREE daily email newsletter.